The Types of Semaglutide Forms

Semaglutide has gained attention for its effectiveness in managing weight and type 2 diabetes.

As interest in this drug grows, many individuals are curious about the different forms of semaglutide available and how they work. Understanding these options can help patients make informed decisions about treatment plans tailored to individual needs and preferences.

This article will explore the FDA-approved uses of semaglutide, including how injectable and oral formulations are used in managing type 2 diabetes and chronic weight management in obesity through Wegovy®.

It'll look into the science behind semaglutide, compare semaglutide tablets vs. injections for weight loss, and discuss the benefits and considerations of each form. This article will also examine the different dosage forms and administration methods and offer insights to help people navigate their options and have meaningful conversations with their healthcare providers about semaglutide treatment.

‍

Key Takeaways

‍

• Semaglutide, in the form of Wegovy®, has been FDA-approved for chronic weight management in specific populations. This glucagon-like peptide-1 (GLP-1) receptor agonist works by increasing insulin release, reducing glucagon secretion, delaying gastric emptying, and suppressing appetite ^[1]. 
• There are three FDA-approved semaglutide products, each with distinct uses and formulations. Ozempic® and Wegovy® are injectable forms, while Rybelsus® is available as a tablet ^[2]. Ozempic®, a once-weekly injection, is primarily used to lower blood sugar levels in type 2 diabetes patients and reduce the risk of major cardiovascular events in adults with established heart disease. Wegovy®, also a once-weekly injection but with a higher dose, is specifically approved for chronic weight management in adults with obesity or overweight individuals with weight-related medical problems.
• Rybelsus®, the first FDA-approved oral GLP-1 receptor agonist, is taken as a daily tablet to lower blood sugar levels in type 2 diabetes patients. This oral form provides an alternative for individuals who may be reluctant to start injectable therapy due to fear of pain or injection site reactions.
• The effectiveness of semaglutide has been demonstrated in various clinical trials. For weight loss, studies have shown that half of the participants using semaglutide lost 15% of their body weight, with nearly a third losing 20% after 68 weeks ^[5]. It's important to note that weight regain tends to occur when individuals stop taking semaglutide, highlighting the need for ongoing treatment ^[6].
• Patients must obtain semaglutide only with a prescription from a licensed healthcare provider and from state-licensed pharmacies or FDA-registered outsourcing facilities. The FDA has raised concerns about compounded versions of semaglutide, which may not be reviewed for safety, effectiveness, or quality.
• Understanding the different forms of semaglutide, their specific uses, and administration methods is essential for making informed decisions about treatment. Patients should consult their healthcare providers to determine the most appropriate form of semaglutide based on their individual needs and medical history.
• Wegovy® is approved for weight loss; Ozempic® is approved for managing type 2 diabetes and cardiovascular risks.

‍

‍

The Science Behind Semaglutide

Semaglutide, a medication for weight management and type 2 diabetes treatment, operates through a complex mechanism that targets various physiological processes. Understanding the science behind semaglutide helps explain its effectiveness in promoting weight loss and improving blood sugar control. Patients should only obtain semaglutide through a prescription from licensed healthcare providers and state-licensed pharmacies. 

When weighing the pros and cons of semaglutide for weight loss, a common concern that arises is that of semaglutide cost. Getting semaglutide from sources like Eden ensures accessibility and affordable options as determined by a healthcare professional. Without insurance, semaglutide can be expensive. Prices can change based on the pharmacy and where patients live, but the cost of semaglutide without insurance can still be costly. Some online coupons or discount programs can help cut the cost of semaglutide treatments.

In order to get approved for semaglutide, individuals must consult with a qualified healthcare professional and should meet some minimum requirements:

‍

1. To lose weight (Wegovy^®): A BMI of 30 or above, or a BMI of 27 or above with at least one health problem related to weight

2. To manage diabetes (Ozempic^®, SubMagna™, and Rybelsus^®): A diagnosis of type 2 diabetes

‍

Individuals will need to talk to a doctor to find out if they can take semaglutide and if it's right for them.

If patients don't have insurance coverage, they have a few options when it comes to how to get semaglutide without insurance. Novo Nordisk, which makes semaglutide products, has programs to help eligible people. Patients can get discounts at different pharmacies using services like Optum Perks. Some pharmacies also make their own version of semaglutide that costs less. Patients can get semaglutide prescriptions online through telehealth services, making it possible for them to buy semaglutide online.

Semaglutide comes in pill form, as a sublingual suspension, and as an injection. Each type has its pros and cons, and there are several factors to consider when deciding between semaglutide tablets vs injections.

‍

Many individuals have successfully lost weight while using semaglutide as part of a medically supervised treatment plan. These semaglutide success stories show how semaglutide can help people lose weight and boost their overall health. Always talk to a doctor to figure out the best way to treat individual conditions. 

‍

GLP-1 receptor agonists

Semaglutide belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. It mimics the natural hormone GLP-1, which is produced in the gut in response to eating. This synthetic version shares a remarkable 94% structural homology with human GLP-1, allowing it to interact effectively with GLP-1 receptors throughout the body ^[1].

The unique structure of semaglutide includes modifications that enhance its stability and extend its half-life to approximately one week. These changes make it suitable for once-weekly administration, potentially improving patient compliance compared to medications requiring daily dosing ^[2].

‍

Effects on blood sugar and appetite

Semaglutide's impact on blood sugar regulation and appetite control stems from its interaction with GLP-1 receptors in various tissues. In the pancreas, semaglutide enhances glucose-dependent insulin secretion, helping to lower blood sugar levels after meals. Simultaneously, it suppresses the release of glucagon, a hormone that raises blood sugar.

The medication also slows down gastric emptying, which leads to a prolonged sense of fullness and contributes to reduced food intake. This effect, combined with its action on the brain's appetite control centers, helps explain semaglutide's ability to decrease hunger and food cravings.

‍

Weight loss mechanisms

Semaglutide's effectiveness in promoting weight loss involves multiple mechanisms. By activating GLP-1 receptors in the hypothalamus and brainstem, areas of the brain involved in controlling hunger and satiety, semaglutide helps reduce feelings of hunger and increase feelings of fullness.

Studies have shown that semaglutide can lead to significant reductions in energy intake. In one trial, participants receiving semaglutide experienced a 24% reduction in total energy intake across all ad libitum meals throughout the day compared to those receiving a placebo.

Semaglutide also appears to influence food preferences and cravings. Research indicates that individuals taking semaglutide report less hunger, better control of eating, and a lower preference for high-fat, energy-dense foods ^[5]. This shift in food preferences may contribute to the medication's overall weight loss effects.

The weight loss achieved with semaglutide is substantial. Clinical trials have demonstrated that patients can lose an average of 14.9% of their body weight after 68 weeks of treatment ^[6]. This level of weight reduction is significantly higher than what is typically seen with lifestyle interventions alone.

The science behind semaglutide reveals a multifaceted approach to weight management and blood sugar control. By mimicking the natural GLP-1 hormone and interacting with receptors throughout the body, semaglutide influences various physiological processes to promote weight loss and improve metabolic health. Its ability to reduce appetite, control food intake, and potentially alter food preferences makes it a powerful tool in the treatment of obesity and type 2 diabetes.

‍

Semaglutide Injections

Semaglutide injections have gained significant attention for their effectiveness in managing type 2 diabetes and promoting weight loss. These injectable forms of semaglutide are available under two brand names: Ozempic® and Wegovy®. Patients should only obtain semaglutide through a prescription from licensed healthcare providers and state-licensed pharmacies.

‍

Brands and indications

Ozempic® is primarily used to help lower blood sugar levels in adults with type 2 diabetes. It has an additional indication to reduce the risk of major adverse cardiovascular events, such as heart attack, stroke, or cardiovascular death, in adults with type 2 diabetes and established heart disease ^[1].

Wegovy® is specifically approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbid condition. It is used in combination with a reduced-calorie diet and increased physical activity ^[2].

‍

Dosing schedule

Both Ozempic® and Wegovy® are administered as once-weekly subcutaneous injections. The dosing schedule for these medications typically involves a gradual increase to minimize gastrointestinal side effects.

For Ozempic®, the recommended starting dose is 0.25 mg once weekly for the first four weeks. After this initial period, the dose can be increased to 0.5 mg once weekly. If additional glycemic control is needed, the dose may be further increased to 1 mg once weekly after at least four weeks.

Wegovy® follows a more extended dose escalation schedule. Treatment begins with 0.25 mg once weekly for the first four weeks, then increases to 0.5 mg for weeks 5-8, 1 mg for weeks 9-12, 1.7 mg for weeks 13-16, and finally reaches the maintenance dose of 2.4 mg once weekly from week 17 onwards.

‍

Injection techniques and sites

Proper injection technique is crucial for the effectiveness and safety of semaglutide injections. The medication should be injected subcutaneously into the abdomen, thigh, or upper arm. It's important to rotate injection sites to prevent irritation or the development of fatty lumps under the skin.

To administer the injection:

‍

1. Clean the injection site with an alcohol swab.
2. Pinch a fold of skin between your fingers to create a firm surface.
3. Insert the needle into the skin at a 90-degree angle.
4. Press the injection button and hold it in place for several seconds to ensure the full dose is delivered.
5. Remove the needle from the skin and dispose of it safely in a sharps container.

‍

It's recommended to inject semaglutide on the same day each week, but the time of day can be flexible. The injection can be given with or without food.

If a dose is missed, it should be administered as soon as possible within 5 days for Ozempic® or within 2 days for Wegovy®. If more time has passed, skip the missed dose and resume the regular schedule.

By understanding the brands, dosing schedules, and proper injection techniques, patients can benefit from semaglutide injections while minimizing potential side effects. Always consult with a healthcare provider for personalized guidance on using these medications.

‍

Oral Semaglutide Tablets

Oral semaglutide, available under the brand name Rybelsus®, represents a significant advancement in the treatment of type 2 diabetes. This once-daily tablet form of semaglutide offers an alternative to injectable formulations, potentially increasing accessibility and adherence for patients who prefer oral medications. Patients should only obtain semaglutide through a prescription from licensed healthcare providers and state-licensed pharmacies.

‍

Unique formulation

Oral semaglutide tablets are co-formulated with an absorption enhancer called sodium N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC). This approach addresses the challenges of oral peptide delivery by protecting semaglutide from enzymatic degradation in the gastrointestinal tract and promoting its absorption across the gastric epithelium. The SNAC technology enables the transcellular absorption of semaglutide, making it possible to achieve therapeutic levels through oral administration.

Despite this technological advancement, the bioavailability of oral semaglutide remains relatively low. Studies have shown that under recommended dosing conditions, the mean bioavailability is approximately 0.8% ^[1]. This low bioavailability is due to the inherent properties of semaglutide as a large peptide molecule, which makes it difficult to absorb through the gastrointestinal tract.

‍

Administration guidelines

To ensure optimal absorption and effectiveness, it's crucial to follow specific administration guidelines for oral semaglutide. The medication should be taken once daily, in the morning, on an empty stomach. Patients are instructed to take the tablet with a sip of plain water (no more than 4 ounces or 120 mL) at least 30 minutes before consuming any food, beverages, or other oral medications ^[2].

The dosage strengths available for oral semaglutide are 3 mg, 7 mg, and 14 mg. For individuals new to semaglutide, the recommended starting dose is 3 mg daily for 30 days. After this initial period, the dose is typically increased to 7 mg daily. If additional glycemic control is needed after 30 days on the 7 mg dose, patients may consider escalating to 14 mg daily.

It's important to note that oral semaglutide tablets should be swallowed whole and not split, crushed, or chewed. If a dose is missed, patients should skip it and resume their regular dosing schedule the next day, avoiding double doses.

‍

Absorption considerations

Several factors can influence the absorption of oral semaglutide. The post-dose fasting time has a significant impact on bioavailability. Gastric fluid composition, which can be affected by food intake and increased water volumes, plays a role in oral semaglutide absorption. To maximize absorption and maintain consistent exposure, it's essential for patients to adhere to the recommended administration guidelines.

While oral semaglutide offers convenience, it's important to note that some patients, particularly those with gastrointestinal issues, may have better results with injectable formulations. Additionally, the strict dosing schedule and fasting requirements may be challenging for some individuals to manage consistently.

‍

Conclusion

The different forms of semaglutide offer patients and healthcare providers a range of options to manage type 2 diabetes and obesity. Injectable versions like Ozempic® and Wegovy®, along with the oral tablet Rybelsus®, each have their own uses and administration methods. This variety allows for personalized treatment plans that take into account individual preferences and medical needs.

It's important to remember that semaglutide treatment is not a one-size-fits-all solution. Patients should work closely with their healthcare providers to determine the most suitable form of semaglutide based on their specific health goals and circumstances. By understanding these options, individuals can make informed decisions about their treatment and take an active role in managing their health.  

‍

‌Disclaimer: The FDA does not approve compounded medications for safety, quality, or manufacturing. Prescriptions and a medical evaluation are required for certain products. The information provided on this blog is for general informational purposes only. It is not intended as a substitute for professional advice from a qualified healthcare professional and should not be relied upon as personal health advice. The information contained in this blog is not meant to diagnose, treat, cure, or prevent any disease. Readers are advised to consult with a qualified healthcare professional for any medical concerns, including side effects. Use of this blog's information is at your own risk. The blog owner is not responsible for any adverse effects or consequences resulting from the use of any suggestions or information provided in this blog.

‍

References 

1. Puckey M. Semaglutide: uses, dosage, side effects, brands. Drugs.com. Published March 13, 2024. Accessed September 28, 2024. https://www.drugs.com/semaglutide.html

‍

2. Merative, Micromedex. Semaglutide (Subcutaneous Route) Proper Use. www.mayoclinic.org. Published 2024. Accessed September 28, 2024. https://www.mayoclinic.org/drugs-supplements/semaglutide-subcutaneous-route/proper-use/drg-20406730?p=1

‍

3. Kommu S, Whitfield P. Semaglutide. PubMed. Published 2024. Accessed September 28, 2024. https://www.ncbi.nlm.nih.gov/books/NBK603723/

‍

4. FDA. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. FDA. Published online May 31, 2023. Accessed September 28, 2024. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss

‍

5. Adkison J. Comparing Ozempic, Wegovy and Other GLP-1 Drugs. GoodRx. Published December 7, 2022. Accessed September 28, 2024. https://www.goodrx.com/classes/glp-1-agonists/glp-1-drugs-comparison

‍

6. Health Focus University Health System. The Difference Between Ozempic, Wegovy & Rybelsus. University Health System. Published 2024. Accessed September 28, 2024. https://www.universityhealth.com/blog/weight-loss-medication

‍

7. Hughes S, Neumiller JJ. Oral Semaglutide. Clinical Diabetes. 2020;38(1):109-111. doi: https://doi.org/10.2337/cd19-0079

‍